Tens of millions to be reinvested in patient care thanks to NHS devices deal
NHS England has yesterday announced a new nationwide system for purchasing expensive medical devices and implants which will see savings of over GBP60 million ploughed back into specialist care in its first two years.
Currently NHS England spends £500 million a year reimbursing specialist units for devices such as implantable cardioverter defibrillators (ICDs) for people with abnormal heart rhythms, bone-anchored hearing aids and bespoke prosthetics.
There are wide variations in the prices hospital trusts pay for the same products, and in the rates of adoption and usage of devices across the country.
A single national approach for purchasing and supplying these devices has now been agreed between NHS England and NHS Business Services Authority. The new system for hospital trusts to order devices for specialist services will be operated by NHS Supply Chain.
By taking a more rigorous commercial approach, the advantage of economies of scale and reducing price variations, it is estimated that tens of millions of pounds can be saved from the annual cost of devices currently being purchased – savings which will be reinvested into other specialist services and treatments.
In future, it is also expected that a national supply chain will improve access for patients to new technologies by allowing novel and effective devices, with proven effectiveness and value to be adopted quickly, easily and at the best price.
Dr Jonathan Fielden, Director of Specialised Commissioning said: “Building on the findings of Lord Carter’s review on productivity and the needs of our patients there is an imperative for specialised services to ensure that every pound of public money delivers the greatest possible benefit to patients.
“By bearing down on price and quality variation and making the most of our national purchasing power, NHS England will now be able to deliver these same high-cost devices for less, freeing up funding to help meet the increasing demands on specialised services from new and effective treatments.”
Whilst all products currently used will continue to be available to clinicians under the new system, further expected benefits will come from working with clinical colleagues to improve clinical practice and device optimisation, as clinicians will be able to choose the optimum device for the patient based on evidence. The data collected will also allow comparisons to be made between equivalent devices in terms of quality, outcomes, value for money and effectiveness to drive further improvements for patients.
All Trusts currently purchasing these high-cost devices will be contacted by NHS England and NHS Supply Chain in a phased approach from April 2016. NHS Supply Chain will provide a full programme of support to each Trust to ensure a smooth migration over to the new arrangements before the end of 2016 .
The central supply chain for devices is scheduled to operate until September 2018 when it is expected that the new transformed arrangements for NHS-wide procurement will be in place.
The devices that this agreement will cover are:
- 3 dimensional mapping and linear ablation catheters (complex cardiac ablation)
- Aneurysm coils and flow diverters for intracranial aneurysms
- Bespoke orthopaedic prostheses
- Circular external fixator frames
- Bone anchored hearing aids
- Carotid, iliac and renal stents
- Deep brain, vagal, sacral, spinal cord and occipital nerve stimulators
- Endovascular stent graft
- ICD (Implantable Cardioverter-Defibrillator)
- ICD with CRT (Cardiac Resynchronisation Therapy) capability
- Intracranial stents
- Intrathecal drug delivery pumps
- Maxillofacial bespoke prostheses
- Occluder, vascular, appendage and septal devices
- Percutaneous valve repair and replacement devices (mitral/pulmonary valve)
- Peripheral vascular stents
- Radiofrequency, cryotherapy and microwave ablation probes and catheters
Latest News from
New NHS measures to improve eye care and cut waiting times30/05/2023 15:25:00
The NHS recently (28 May 2023) published new clinical guidance which could reduce waiting times for eye care services for patients in England.
Tennis star Sir Andy Murray OBE backs ‘parkrun for the NHS’30/05/2023 14:15:00
Britain’s most successful male tennis player, Andy Murray, is encouraging people across the UK to take part in ‘parkrun for the NHS’ to celebrate the NHS’s 75th birthday and to take steps towards a more healthy, active lifestyle.
Sara Hurley, the Chief Dental Officer for England, to stand down26/05/2023 10:15:00
Sara Hurley, the Chief Dental Officer for England is standing down after eight years in the job to focus on her new roles as a Non-Executive Director at Surrey Heartlands ICB and as an independent director at the University of Suffolk.
World-first NHS test to curb transfusion side-effects for thousands with inherited blood disorders23/05/2023 14:15:00
The NHS is set to introduce a new genetic blood-matching test for thousands living with sickle-cell disease or thalassemia that could reduce painful side-effects of transfusion treatments.
Government meets target one year early to recruit primary care staff22/05/2023 11:17:00
The government has delivered on its commitment of recruiting 26,000 more primary care professionals – such as dieticians and paramedics – in GP practices.
NHS hits three million spring boosters19/05/2023 15:05:00
The NHS COVID-19 Vaccination Programme has vaccinated almost half of those eligible with a spring booster a month after the campaign’s formal launch.
Government meet target 1 year early to recruit primary care staff18/05/2023 14:22:00
The government has delivered on its’ commitment of recruiting 26,000 more primary care professionals – such as dieticians and paramedics – in GP practices.
NHS rolls out new ‘lifeline’ combination therapy for hundreds of women with womb cancer18/05/2023 13:10:00
Hundreds of women with advanced womb cancer in England are to be offered a new ‘lifeline’ option from today, as the NHS rolls out a life-extending new combination therapy that can halt the progression of the disease for twice as long as chemotherapy.